We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current SIGHT market cap is 31.9M. The company's latest EPS is EUR -0.3346 and P/E is -1.23.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 4.91M | 7.72M | 7.71M | 4.87M | 2.96M |
| Operating Income | -30.3M | -24.93M | -28.13M | -27.84M | -29.7M |
| Net Income | -30.87M | -34.02M | -28.62M | -27.63M | -26.22M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 32.48M | 47.36M | 56.65M | 25.94M | 9.13M |
| Total Liabilities | 21.97M | 35.69M | 40.66M | 41.22M | 39.83M |
| Total Equity | 10.52M | 11.67M | 15.99M | -15.28M | -30.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -28.11M | -15.04M | -17.14M | -33.75M | -24.66M |
| Investing | -102k | -376k | -16k | 172k | 209k |
| Financing | 21.25M | 33.86M | 23.74M | 96k | 15.86M |
| Market Cap | 31.9M |
| Price to Earnings Ratio | -1.23 |
| Price to Sales Ratio | 10.85 |
| Price to Cash Ratio | 15.07 |
| Price to Book Ratio | -1.05 |
| Dividend Yield | - |
| Shares Outstanding | 78.37M |
| Average Volume (1 week) | 47.1k |
| Average Volume (1 Month) | 44.81k |
| 52 Week Change | -44.32% |
| 52 Week High | 1.148 |
| 52 Week Low | 0.2995 |
| Spread (Intraday) | 0 (0.98%) |
| Company Name | GenSight Biologics S.A. |
| Address |
74, rue du faubourg saint-antoine paris, paris 75012 |
| Website | https://www.gensight-biologics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
